Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01882270 · ClinicalTrials.gov registry record
Third Molar Clinical Trials: Pericoronitis Studies
A clinical trial, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- 115
- Enrollment target
NCT01882270: Completed study, sponsored by University of North Carolina, Chapel Hill.
NCT01882270 is a clinical trial that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 115 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01882270 has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- 115 participants
- Enrollment target
Study Summary
The purpose of this research study is to find out if the infection around 3rd molars and the resulting inflammation around the gum also produces a general systemic inflammation.
Primary Outcome
HRQOL data each day for seven days: Subject diary Pain 7pt Likert scale for worst/average pain in past 24h Gracely Scales for current sensory perception/affect Lifestyle, oral function, other symptoms 5pt Likert type scale Global QOL OHIP 14
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2008-01 |
| Est. Completion | 2013-12 |
What the finished NCT01882270 record still lists
NCT01882270 is an observational study that tracks outcomes without assigning an intervention. The registered 115 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01882270 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01882270 about?
NCT01882270 is a clinical study titled "Third Molar Clinical Trials: Pericoronitis Studies". The purpose of this research study is to find out if the infection around 3rd molars and the resulting inflammation around the gum also produces a general systemic inflammation.
What is the current status of trial NCT01882270?
This trial is currently completed. The enrollment target is 115 participants. The study started on 2008-01. Estimated completion is 2013-12.
Who is sponsoring clinical trial NCT01882270?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02346929 · 115 participants · NA
Hematoma Block for Distal Radius Fracture
- NCT03394365 · 115 participants · Phase 3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- NCT03907475 · 115 participants · Phase 2
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
- NCT05086692 · 115 participants · Phase 1
A Beta-only IL-2 ImmunoTherapY Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia